A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs RX 5902 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Rexahn Pharmaceuticals
- 11 Oct 2017 Planned patient number kept as per MR 9211995.
- 11 Oct 2017 CTP 256876 has been integrated as per jnm0930 BAC dated 5 Apr 2017.
- 27 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History